FyMed Announces Top-Line Results Demonstrating Superiority of FY103B...

FyMed, Inc. today announced top-line results from studies of FY103B, its new NSAID candidate, which demonstrated significant superiority over celecoxib in terms of efficacy and safety.(PRWeb April 24, 2014)Read the full story at http://www.prweb.com/releases/2014/04/prweb11785126.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news